Maridebart cafraglutide

GLP-1 agonist + GIP antagonist (bispecific) · Amgen

Top dose
280 mg Q4W
Weight loss
-19.9%
at week 52 · efficacy
AE discontinuation
14.0%
Status
phase 2

Weight loss trajectory #

Weight loss trajectory for MariTide 280 mg Q4W over 52 weeks in the Phase 2 obesity (NCT05669599) trial.

Pivotal trial #

Trial
Phase 2 obesity (NCT05669599)
Indication
obesity (no T2D)
Duration
52 weeks
ClinicalTrials.gov
NCT05669599
Sponsor
Amgen

Notes #

Phase shown reflects the DATA: the -19.9% is from the Phase 2 dose-ranging trial (NCT05669599, primary complete Oct 2024). The Ph3 MARITIME program is ongoing but has not read out. Phase 3 program expanding 9->12 trials by YE 2026. Positioned as 4-6 injections/year maintenance drug. NEJM 2025. ae_disc not directly comparable: GI-led discontinuation is strongly escalation-dependent (up to ~27% in no-escalation arms vs <=8% with dose escalation), so the single 14% value spans arms rather than a clean headline dose.